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Abstract: Lung cancer is a highly prevalent disease worldwide. Currently, there are more than 150 million patients with 
lung cancer in the world, with more than 1 million new cases diagnosed per year. Tumoral angiogenesis is an important 
hallmark of this disease, but despite being extensively studied, the complete angiogenic mechanisms are not fully eluci-
dated. Recent studies have reported a correlation between pharmacological inhibition of these angiogenic mechanisms and 
improvement of overall survival in lung cancer patients, mainly for those in advanced stages. The family of vascular endo-
thelial growth factor (VEGF) proteins has critical roles in tumoral angiogenesis. An interaction between VEGF-A and 
VEGF receptor 2 (VEGFR-2) is the main pathway of activation and maintenance of angiogenesis. In tumors, this process 
is intimately correlative with progression and metastasis. Some studies suggested that serum levels of VEGF are higher in 
patients with lung cancer, especially in some types of non-small cell lung cancer (NSCLC). Other studies revealed that 
genetic polymorphisms of VEGF correlate with susceptibility, prognosis, and therapeutic response of some patients with 
NSCLC. This paper aims to review the impact of angiogenesis, especially on VEGF pathways, in NSCLC, and highlights 
the relevance of known and new patents disclosed of anti-angiogenic therapies in these patients.  
Keywords: Angiogenesis, antineoplastic drug combination, biological markers, neovascularization, non-small cell lung cancer, 
pathology, polymorphism, vascular endothelial growth factor. 
1. REVIEW CRITERIA 
 A systematic search was made in four important data 
bases: PubMed (www.pubmed.com), Scopus (www.scopus. 
com), Freepatentsonline (www.freepatentsonline.com) and 
Directory of Open Access Journals (www.doaj.org), with the 
following terms: “VEGF polymorphisms and lung cancer”; 
“antiangiogenic chemotherapy”; “angiogenesis mechanisms 
and lung cancer”; “angiogenesis and VEGF polymor-
phisms”; “VEGF drugs”; “VEGF polymorphisms and lung 
cancer prognosis”. Studies dated between 1971 and 2011 
were selected and evaluated. Case reports were not consid-
ered. 
2. INTRODUCTION 
 Lung cancer is a disease with high mortality and morbid-
ity, currently affecting more than 1 million people worldwide 
[1]. In 2006, approximately 12% of all cancer cases were  
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diagnosed as lung cancer (LC) [2]. Non-small cell lung can-
cer (NSCLC) is the most common of LC types, accounting 
for more than 80% of all new cases in North America [1, 2]. 
It is an extremely lethal malignancy: all histological types 
have a 5-year survival rate of only ~15% [3, 4]. Histologi-
cally, the major subtypes are: adenocarcinoma (the most 
frequent), squamous cell carcinoma, and large cell carcinoma 
[5]. Cigarette smoking is related with almost 87% of lung 
cancer-related deaths [1, 6]. Evaluations of population pat-
terns in smoking prevalence indicate that, in coming years, 
LC rates will probably decrease in Western countries due to 
lifestyle changes (mostly due to anti-smoking campaigns) 
[6]. Nevertheless, other factors account for cancer suscepti-
bility, such as gender, ethnicity, radon exposure, clinical 
antecedents of lung tuberculosis, and occupational lung dis-
ease [2, 7]. Lung carcinogenesis is influenced by the cell’s 
ability to repair DNA lesions induced by external agents, 
such as tobacco and nitrosamines that initiate the carcino-
genic process [4]. These genetic lesions will affect genes that 
regulate cancer hallmark mechanisms: uncontrolled cellular 
proliferation; escape from programmed cell death; unlimited 
replicative potential; tissue invasion and metastization; and 
genesis of new blood vessels from pre-existent vasculature 
(angiogenesis) [8]. Therefore, the angiogenic process is a 
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paramount feature of NSCLC and the introduction of tar-
geted therapies directed at key molecules of this process, like 
bevacizumab, a monoclonal antibody against vascular endo-
thelial growth factor (VEGF), have shown great benefits in 
NSCLC patient treatment, especially when the malignancy is 
in advanced stages [8-11]. This paper aims to review the 
impact of angiogenesis, especially of VEGF pathways, in 
NSCLC, the relevance of polymorphisms in angiogenesis-
related genes, and discuss the impact of known and new pat-
ents of anti-angiogenic therapies on these patients.  
3. ANGIOGENIC MECHANISMS AND VEGF FAM-
ILY 
Mechanisms of Tumor Vessel Creation Through VEGF 
Pathway 
 The creation of new tumor vessels influences not only the 
progression but also LC clinical behavior [12]. It is therefore 
fundamental to understand such mechanisms in order to ac-
quire a better insight of the physiopathology and potential 
targeting treatments of this disease [12]. Since 1971, when 
Judah Folkman published his innovative hypothesis on tu-
moral vascularization [13], angiogenesis has been progres-
sively considered responsible for the evolution of many can-
cer types [12, 14]. Folkman suggested that tumors above 2 
mm would need new blood vessels in order to develop and 
grow, and predicted the existence of a tumor angiogenic fac-
tor responsible for inducing genesis of such vessels [15]. 
Currently, we know that the VEGF family is the main driver 
of this process, comprising six members: VEGF-A, -B, -C, -
D, and -E and placental growth factor (PlGF) [16]. VEGF-A 
is the most important member and it is responsible for physi-
ologic and pathologic mechanisms of angiogenesis [12]. 
Normally, it acts through binding with VEGF receptor 2 
(VEGFR-2) generating a cascade of intracellular signaling, 
leading to activation of transcription factors in the nucleus 
that will ultimately lead to new vessel formation [10] as 
shown in Fig. (1). VEGF-A is a glycoprotein transcribed by 
a gene located on chromosome 6 (6p21.3). VEGF-A, or sim-
ply VEGF, exists in 6 isoforms categorized by the length of 
amino acid chains, VEGF121, VEGF145, VEGF165, VEGF183, 
VEGF189, and VEGF206. In vivo, only three isoforms have 
been related to angiogenesis: VEGF121, VEGF145, and 
VEGF165. The latter, with 165 amino acids, has been demon-
strated to be a predominant isoform secreted by malignant 
and benign cells [17]. One of the major inducers of VEGF is 
hypoxia, which activates the hypoxia-inducible factor (HIF) 

















Fig. (1). Angiogenesis pathway. Adapted with permission from reference [12]. The major mediator of angiogenesis is VEGF, which circu-
lates basically in two isoforms, VEGF-A121 and VEGF-A165. Many factors, both environmental and genetic, may influence VEGF expres-
sion. The binding of VEGF-A to VEGFR-2, followed by the dimerization of the receptor, leads to a cascade of signaling pathways responsi-
ble for the many steps of tumor progression: vascular proliferation, cell proliferation, cell survival and migration.  
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meostasis and it is produced through a cis-acting sequence 
required to increase erythropoietin gene transcription in re-
sponse to hypoxia [18]. HIF-1 is responsible for activating 
the transcription of genes encoding important signaling pro-
teins shown in Table 1, such as angiogenic factors, cellular 
surface receptors, and extracellular matrix proteins, thus 
promoting the first steps towards new vessel genesis [12, 
18]. Paracrine mechanisms generated through VEGF produc-
tion in tumor cells may also influence angiogenesis path-
ways, but those cells cannot adequately respond to the stimu-
lus if they do not have enough cell membrane receptors for 
that purpose. Paradoxically, endothelial cells recruited dur-
ing angiogenesis produce great amount of receptors, but pro-
duce little or no VEGF ligand. In this context, the amount of 
VEGF necessary to propel angiogenesis comes from several 
host cells in human body, like platelets, smooth muscle cells, 
and stromal cells, which, together, produce the necessary 
amounts of VEGF for angiogenesis to begin [19-21]. These 
vessels are significantly different from normal vasculature 
and do not have the same function. The structural heteroge-
neity of the new vasculature contributes to diversified behav-
ior in each cancer regarding growth and tumor development 
[22] Table 2.  
Table 1. Categories of HIF-1 Target Genes and Corre-
sponding Proteins. 
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Abbreviations: VEGF, vascular endothelial growth factor; PDGF, platelet-derived 
growth factor; VEGFR, VEGF receptor. 
 
VEGF Family 
 The other VEGFs family members are important for 
many diverse mechanisms of new vessel creation. The 
VEGF-B and PlGF act through VEGFR-1 in angiogenesis 
and in vasculogenesis. Although this receptor has higher 
affinity to VEGF than VEGFR-2, the interaction between 
VEGF-B and VEGFR-1 does not have good expression in 
angiogenesis pathways and its role remains unclear at this 
time [12]. The VEGF-C [3] and its close homolog, VEGF-D 
[20], influence lymphangiogenesis, through VEGFR-2 and 
VEGFR-3, and are also important in tumor metastization [3, 
20]. The VEGF-E concurrent to VEGF-A, VEGF-B and 
PlGF acts by binding to neutrophilin 1, a nonkinase receptor 
expressed in vascular endothelium, neurons and tumor cells, 
potentiating VEGF-A´s binding to VEGFR-2, thus promot-
ing the first steps of angiogenesis [16].  
Notch-Delta-Like Ligand 4 (Dll4) Pathways 
 Recently, another pathway has proven to be very impor-
tant for angiogenesis, the notch-delta-like ligand 4 (Dll4) 
pathway [23, 24]. The Notch membrane receptors are neces-
sary in order to generate stimuli that signal important intra-
cellular mechanisms [23]. The Dll4/Notch pathway acts by 
controlling the stimulus of angiogenesis [12, 23, 24]. Some 
studies suggest that tumors that depend on VEGF are able to 
induce the expression of Dll4 in endothelial cells and nega-
tively regulate the vascular growth as a mechanism to control 
the angiogenic rate [23]. These signaling pathways act as 
brake mechanisms for the production of excessive amounts 
of blood vessels, promoting therefore the stabilization of an 
angiogenic process [23]. Therefore, if there is a blockade in 
the Notch/Dll4 pathway, this negative feedback will be de-
stroyed and in consequence an excessive and unorganized 
production of blood vessels will take place favoring tumor 
progression [12]. Even so, these vessels are structurally 
abnormal and do not possess a good tissue perfusion, leading 
to tumoral hypoxia [12, 23]. 
VEGF Prognostic Value 
 The high expression and activity of VEGF has been ob-
served in 30-40% of NSCLC [10]. Over the last decade, sev-
eral studies have reported that VEGF influences NSCLC 
tumor behavior [3, 9, 10, 14, 25-28]. An immunohistochemi-
cal study of 102 NSCLC patients reported a higher expres-
sion of VEGF-A in adenocarcinomas when compared to 
squamous cell carcinomas [25]. However, VEGF-A expres-
sion was not associated with NSCLC prognosis [25]. Re-
cently, another study [9] enrolling 134 patients diagnosed 
with NSCLC, evaluated the plasma levels of total VEGF 
during the treatment with platinum-based chemotherapy. The 
patient plasma VEGF baseline cut off value considered in 
this study was 275.2pg/mL, but it could not be related with 
overall survival (OS). Nevertheless, this study showed that 
patients in remission had a significant reduction of plasma 
VEGF levels in subsequent chemotherapy cycles, which 
suggested the utility of VEGF as a predictive biomarker in 
this type of patient [9]. Another study with 118 NSCLC pa-
tients showed that patients who present serum VEGF levels 
630pg/mL had a significant OS increase as compared to 
those with higher levels (p = 0.04) [29]. It is important to 
4    Recent Patents on Anti-Cancer Drug Discovery, 2012, Vol. 7, No. 1 de Mello et al. 
note that many factors may influence the results of the previ-
ously discussed studies, namely the isoform of VEGF that 
was quantified, or whether the total VEGF is measured, or 
even the collecting environment, storage and tubes used for 
venipuncture. The use of serum levels (and not plasma levels 
obtained from EDTA tubes) is recommended, processed un-
til 1 hour after venipuncture and stored after centrifugation at 
-80ºC [10]. Overall, several studies have shown that serum 
VEGF can be an important and practical biomarker for the 
follow up of patients with lung cancer, allowing the possibil-
ity to individualize chemotherapy and perhaps predict the 
aggressiveness of several histological types [9, 10, 14, 24]. 
In 2010, Heymach et al. [30] studied 31 cytokines in 33 early 
stage NSCLC patients treated with pazopanib. They reported 
the important role of interleukine 4 and soluble VEGFR2 in 
tumor shrinkage, thus suggesting the central role of angio-
genic biomarkers in tumor response [30]. In the E4599 phase 
II and phase III trials, many other biomarkers were evalu-
ated, and good prognostic value of intracellular adhesion 
molecule 1 (ICAM-1) was found [31]. In the same study, 
serum VEGF was found to be a good predictive biomarker 
for patients treated with bevacizumab, but did not signifi-
cantly correlate with OS [31]. Also, they suggested ICAM-1 
as a strong prognostic marker for overall survival, and the 
circulating endothelial progenitor cells as a promising 
marker due to their responsiveness to anti-angiogenic agents. 
4. ANTI-ANGIOGENIC TARGETED THERAPIES 
AND NEW PATENTS 
 For a long time, conventional chemotherapy, based 
mainly on platinum, has not shown satisfactory results in the 
treatment of lung cancer, especially in advanced stages, with 
an average OS under 10 months after diagnosis [1, 28]. Since 
then, targeted therapies, especially those associated with 
anti-angiogenic mechanisms such as tyrosine kinase inhibi-
tors (TKI) and monoclonal antibodies, have shown some 
improvement in OS for several cancer types, including ad-
vanced stages of NSCLC Table 3 [11, 22, 28, 32-36]. TKIs 
are the compounds that selectively target the intracellular 
tyrosine kinase domain of receptors and act by competing 
with the ATP-binding site, thereby inhibiting the tyrosine 
phosphorylation and blocking the signaling pathways. The 
monoclonal antibodies usually bind to ligands and decrease 
the angiogenic activity by blocking its interaction with mem-
brane receptor cell signaling.  
VEGFR, EGFR and RET Multi-Target Tyrosine Kinase 
Inhibitors  
 The increased knowledge of the molecular mechanisms 
underlying cancer development and progression leads to the 
development of specific targeted therapies against key cellu-
lar players, with outstanding results in some tumor types [37-
39]. Some drugs, mainly of the TKIs category, targeting the 
three VEGF receptors, VEGFR-1, VEGFR-2 and VEGFR-3, 
have been evaluated in phase II and phase III studies for their 
anti-angiogenic and clinical action. One example is the 
sorafenib, an oral anti-kinase inhibitor with anti-angiogenic 
and anti-proliferative activity; but it has not demonstrated 
clinical benefit in addition to standard chemotherapy in 
phase III studies [40, 41]. Another example is vandetanib, a 
multitarget TKI, which targets VEGFR2, epidermal growth 
factor receptor (EGFR) and RET, and has an improvement in 
progression-free survival (PFS) in phase II studies of 
NSCLC patients, as monotherapy or in combination therapy 
[36], and also when compared with gefitinib [42]. One study 
presented at the American Society of Clinical Oncology 
(ASCO) congress in 2010 confirmed vandetanib superiority 
PFS versus placebo in NSCLC patients, but did not demon-
strate an OS benefit [43]. Currently the OS study results are 
not very consistent regarding this molecule, despite its bene-
fit on PFS [44].  
VEGFR, EGFR, PDGF, FGF and PlGF receptors tyro-
sine kinase inhibitors  
 Many other TKIs target multiple receptors, as is the case 
with sunitinib, montesanib, and the axitinib, which block the 
Table 2. Differences between Normal and Tumor Vasculature. 
Normal Vasculature  Tumor Vasculature  
Organized  Disorganized  
Evenly distributed  Unevenly distributed  
Uniform Shaped twisted  
Nonpermeable  Leaky  
Vascular pressure is greater than interstitial pressure Vascular pressure is similar to tumor  interstitial pressure 
Properly matured  Immature  
Supporting cells present (e.g., pericytes) Absence of supporting cells 
Appropriate membrane protein expression Inappropriate membrane protein expression 
Independent of cell survival factors Dependent on cell survival factors (e.g., VEGF) 
Homogenous oxygenation of tissue within O2 diffusion limit Focal hypoxic and anoxic regions  
Abbreviations: VEGF, vascular endothelial growth factor. 
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activity of VEGFR-1, VEGFR-2, VEGFR-3, EGFR, and 
PDGF receptors. Their LC anti-tumor properties are cur-
rently being studied in phase I and phase II studies [34, 35, 
45-50], but until this moment no significant data has been 
disclosed [51]. Nevertheless, some studies raised high expec-
tations, like axitinib, which has proved to be a very powerful 
drug in a phase II study with an OS of 14.8 months [52]. The 
inhibition of endothelial proliferation via endostatin pathway 
was also recently showed to be promising. A novel invention 
in this field has been demonstrated to inhibit angiogenesis in 
mice lung cancer cells. This patent is a recombinant en-
dostatin inhibitor (US7867975) with molecular weight be-
tween 18 to 20KDa and is capable of inhibiting endothelial 
cell proliferation in vitro [53]. Recently, patents such as 
BIBF 1120, have emerged in phase I and II trials as potent 
TKIs that simultaneously inhibit VEGFR 1-3, fibroblast 
growth factor receptors 1-3, and placental-derived growth 
factor  and  [54]. In fact, the results were not enough to 
conclude on OS and PFS, but the drug was well tolerated 
when used in a continuous treatment regimen. Another in-
vention (US7875603) showed some benefit by inhibiting 
VEGFR in lung cancer treatment, as such as breast, colorec-
tal, prostate and ovarian [39]. This invention decreases angi-
ogenic activity by blocking the VEGF receptors. 
EGFR Tyrosine Kinase Inhibitors  
 At the end of the of 1990´s, EGFR was shown to play an 
important role in tumor biology and behavior [55]. EGFR 
overexpression is present in approximately 43 to 83% of 
NSCLC, being more common in squamous cell carcinoma 
(70%), followed by adenocarcinoma (50%), and to a lesser 
extent in large cell carcinoma. This phenomenon is very rare 
in SCLC [55-58]. Its stimulation by external factors activates 
the intracellular signaling and cascades, through the down-
stream signaling pathway phosphoinositide 3-kinase (PIK3) 
regulation, Akt and mammalian target of rapamycin 
(mTOR), or through Ras-Raf-Mek pathway (MAPK), in-
duces the expression of VEGF, and influences cellular pro-
liferation, mobilization and angiogenesis [4, 59]. In tumor 
cells, it was found that the activation of cell proliferation 
mediated by EGFR would no longer need the external stimu-
lus, but act independently and autonomously [55]. In the 
particular case of NSCLC, it was shown that the EGFR over-
expression, as well as specific somatic mutations occurred in 
their intracellular domain with tyrosine kinase activity (be-
tween exons 18 and 21), were the factors of poor prognosis, 
being significantly related with stage, survival and chemo-
therapy response [55, 60-63]. This data led to the develop-
ment and study of various substances, among which are 
monoclonal antibodies (e.g. cetuximab (Erbitux
®
), already 
approved for the treatment of colorectal carcinoma, but still 





) [55, 60, 64-67]. After, some papers [68-
70] started to evaluate which was the best method to assess 
EGFR role in the response, PFS and OS of patients with 
NSCLC treated with gefitinib: EGFR mutation, copy number 
or quantitative of EGFR assessed by Fluorescence in situ 
hybridization (FISH) or real-time polymerase chain reaction 
(PCR) or EGFR detected by immunohistochemistry. The 
EGFR mutation (deletion in exon 19 or L858R in exon 21) 
has shown high sensitive (92%) and moderately specific 
(76%) for predicting response to EGFR TKI chemotherapy. 
Nowadays, this test is the preferred method for selecting 
patients with advanced, chemorefractory lung adenocarci-
noma who are most likely to respond to erlotinib or gefitinib 
treatment [62]. The other methods, such as copy number by 
FISH or immunohistochemical positivity, may have a role 
for PFS predicting within an EGFR-mutated subset of pa-
tients, but they are not independently informative tests [62, 
63].  
 Two TKI´s of EGFR, gefitinib and erlotinib, are cur-
rently used for the treatment of adenocarcinoma and 
NSCLC. Erlotinib was approved for refractory locally ad-
vanced/metastatic NSCLC [71]; and, since May 2010, gefit-
inib was approved by European Medicine Agency (EMEA) 
for use in first line treatment of metastatic advanced NSCLC, 
EGFR mutation positive based on its PFS and OS benefits 
when compared with the carboplatin-paclitaxel-treated group 
[72, 73] and the cisplatin-docetaxel-treated group [74]. Er-
lotinib in April 2010 was also approved for maintenance 
treatment in advanced NSCLC patients with stable tumor 
disease based on SATURN study [63, 72, 75]. Therefore, 
these therapies cannot only have an anti-neoplastic, but also 
an anti-angiogenic activity. Currently, the therapeutically 
resistance mechanisms for EGFR TKI are the subjects of 
discussion. There are several documented resistance point 
mutations to gefitinib and erlotinib, such as T790M, L747S 
and D761Y [56, 63]. The T790M is the most common sec-
ondary resistance mutation reported, accounting for about 
50% of tumor relapse from prior TKI treatment [76].  
The Role MET Inhibitors Drugs 
 In the last three decades, MET proto-oncogene was dis-
covered that encodes the high affinity cell surface receptor 
(c-MET) for hepatocyte growth factor (HGF) and also con-
trols carcinogenesis steps, including cell growth, prolifera-
tion, invasion and protection from apoptosis [77]. Recently, 
MET inhibitor patents are emerging as a new class of target 
therapies that promise good results in NSCLC patients [78]. 
The dual EGFR-MET inhibition [79] or VEGF/KDR recep-
tor-HGF/c-MET dual inhibitor (US7790729) [78] are good 
strategies to improve anti-angiogenic approach by circum-
venting the ability of tumor cells overcome VEGF inhibition 
alone or overcoming MET-mediated resistance to EGFR 
inhibitors [78, 79]. In 2010, at the annual ASCO meeting, 
Wakelee et al. reported a new patent, XL184, that is an oral 
potent inhibitor of MET, VEGFR2 and RET in association 
with erlotinib in NSCLC patients. Its use is encouraged 
mainly in patients with erlotinib resistant and EGFRT790M 
and MET amplification [80]. Another recent patent, 
ARQ197, is a selective non ATP competitive inhibitor of c-
MET that, when combined with erlotinib in treatment of sec-
ond/third line EGFR inhibition, a naïve NSCLC increase of 
PFS was shown, mainly among patients with non-squamous 
histology, K-RAS mutations, and EGFR wild-type status 
[79]. In 2011, a new patent (US787211) provided a good 
weapon to suppress tumor growth toward c-MET pathways. 
This invention acts using RNA interference (RNAi) technol-
ogy and adenovirus carrying siRNA (Ad met siRNA) target 
sequences that substantially reduces MET expression in hu-
man tumors cells. Ad met siRNA kills cancer cells by induc-
ing apoptosis. In vivo, intra-tumoral infection with c-met 
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siRNA adenovirus vectors produces significant reduction in 
tumor growth [81]. Thus, this might be another choice in 
future to use associated with EGFR TKIs chemotherapies. 
Anti-Angiogenic Monoclonal Antibody: Bevacizumab 
 Currently, drugs like bevacizumab act basically by reduc-
ing the interactions between VEGF and its receptors, dimin-
ishing the intracellular signaling that triggers the growth of 
new vessels, therefore improving the OS and also the PFS 
[14, 36]. Recently, some clinical trials have been developed 
aiming at demonstrating the effectiveness of new specific 
anti-angiogenic drugs for the improvement of the NSCLC 
approach as reported in Table 3 [11, 32-36, 41, 42, 46-50, 
52, 71, 82-87]. In 2006, the Eastern Cooperative Oncology 
Group (ECOG) in a phase III trial (ECOG 4599) involving 
878 patients diagnosed with advanced stage NSCLC showed 
[33] that adding bevacizumab, a monoclonal anti-body 
against VEGF, to the conventional chemotherapy protocols 
based on platinum, significantly increases the OS of 10.3 
months in a group treated only with chemotherapy for 12.3 
months in a group that underwent chemotherapy and bevaci-
zumab (hazard ratio = 0.79, p = 0.003). There was also an 
increase in PFS from 4.5 months to 6.2 months in the group 
with bevacizumab (hazard ratio = 0.66, p < 0.001), and the 
therapeutic response also increased [33]. This monoclonal 
antibody was later approved by the FDA in 2006 for ad-
vanced NSCLC treatment [1]. Nevertheless, the same study 
[33] demonstrated that this treatment must be carefully con-
sidered in order to avoid the risk of thromboembolic events 
and even fatal hemorrhagic events more frequently associ-
ated to central tumors with squamous histology [11, 33]. The 
AVAiL phase III trial showed an arguable benefit of adding 
bevacizumab to conventional therapy in advanced NSCLC 
patients when the PFS improvement was not clinically sig-
nificant, but the design could not compare with the best dos-
age (7.5mg/kg or 15mg/kg each 3 weeks) [11]. Recently, the 
final analysis of AVAiL resulted in still minor clinical PFS 
improvement when bevacizumab is combined with gemcit-
abine and carboplatinum, and without improvement in OS 
[88]. The ATLAS and PASSPORT studies demonstrated that 
it could be safely used in patients with brain metastasis [89] 
since they are first treated with brain radiotherapy and with-
out progression evidence by imaging studies after four weeks 
since beginning treatment [90, 91]. Currently, bevacizumab 
is the only anti-angiogenic target therapy approved by FDA 
for NSCLC patients, especially in those aged less than 70 
years old, stage IV and performance status zero to one [1, 
90].  
New Patents in Anti-Angiogenic Monoclonal Antibody 
Field 
 In the sequence, new patents such as VC300 
(US7740844) [92], US7691977 [93], AMG102 [94], Met-
Mab [95], VEGF165b (US7820178) [96] and US7875704 
[97] emerged as promising inventions in the angiogenesis of 
monoclonal antibodies field as also shown in Table 4 and 
Fig. (2). VC300 is a recent monoclonal antibody that binds 
to amino acid residues Asn100 and Lys107 in human VEGF 
neutralizing its activity. This invention can be prepared by 
recombinant technology and it can be incorporated into 
pharmaceutical compositions suitable for an administration 
to a subject [92]. Another interesting new US patent 
(US7691977) of the last year was novel antibodies polypep-
tide sequence capable of binding the rodent and human 
VEGF with Kd values within 10 fold of each value wherein 
they inhibit the binding of VEGF to VEGFR. The antibody 
comprises a complementarity-determining region H1 (CDR-
H1) comprising the amino acid sequence ASWIH, a CDR-
H2 comprising the amino acid sequence AIYPYSGYTNY-
ADSVKG, a CDR-H3 comprising the amino acid sequence 
WGHSTSPWAMDY, a CDR-L1 comprising the amino acid 
sequence RASQDVSTAVA, a CDR-L2 comprising the 
amino acid sequence SASFLYS, and a CDR-L3 comprising 
the amino acid sequence QQSYTTPPT. Further evaluations 
are warranted in this field in order to assess its feasibility in 
solid tumor, especially NSCLC [93]. In a phase Ib study, the 
AMG102, a monoclonal antibody against HGF, showed a 
possible benefit in solid tumor dimension reduction when 
combined with bevacizumab, but further evaluation with this 
patent is warranted [94]. Also, the monoclonal antibody act-
ing directly against MET showed good clinical results. 
MetMab (Genentech) is a human recombinant antagonist of 
HGF-MET signaling pathway, demonstrated to be well tol-
erated in association with bevacizumab and effective in a 
phase Ib trial [95] and also with minor PFS improvement 
[98, 99].  
 Furthermore, as result of differentially splicing into a 
previously undescribed exon, exon 9, a new VEGF isoform 
in kidney cells was discovered with anti-angiogenic activity 
(called VEGF165b, with 165 polypeptides sequence). This 
novel isoform may have an importance in future cancer 
treatment protocols [96]. The PlGF is another molecule that 
modulates angiogenesis. In 2011, a new patent provided a 
monoclonal antibody that inhibit PlGF binding with its re-
ceptor that can be used to significantly reduce the tumori-
genicity steps with a decrease of side effects caused by an 
inhibition of physiological angiogenesis [97]. Thus, as mo-
lecular mechanisms of tumor biology are elucidated, new 
therapeutic possibilities are developed in order to improve 
the treatments for the NSCLC patients, as monotherapy or in 
association with the existent chemotherapy protocols [100]. 
5. GENETIC POLYMORPHISMS RELATED TO THE 
ANGIOGENESIS PATHWAYS 
 The human VEGF gene has more than 15 single nucleo-
tide polymorphisms (SNPs) identified to date [101-103]. Due 
to the central roles of VEGF in angiogenesis, some of these 
gene polymorphisms have been recently studied in the con-
text of different tumor types, including breast cancer [104], 
malignant melanoma [105], prostate cancer [106], and lung 
cancer [101, 103, 107-112]. Importantly, particular polymor-
phic variants have been shown to be functional [113-115] 
(i.e. they correlate with VEGF production), and have already 
been associated with tumor risk, angiogenesis, vascular den-
sity, and prognosis [101, 103-112]. Table 5 summarizes the 
major conclusions of studies addressing the relevance of 
individual VEGF polymorphisms in the context of lung can-
cer, particularly as putative risk factors for developing lung 
cancer and mediators of VEGF levels, tumor behavior, and 
patient prognosis. Table 6 summarizes the studies addressing 
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Table 3. Summary of Clinical Trials Evaluating Anti-Angiogenic Therapy in NSCLC Patients. 
Reference Phase Treatment n OS(month) RR(%) 
Bevacizumab 
CBDCA + Pac* 427 10.3 35 33 III 
CBDCA + Pac* + bevacizumab 15mg/kg 440 12.3 15 
CDDP + gem ** + placebo 347 NR 20.1 
CDDP + gem **+ bevacizumab 7.5mg/kg 345  34.1 
11 III 
CDDP + gem **+ bevacizumab 15mg/kg 351  30.4 
Sorafenib 
46 II Sorafenib 400mg 15 NR 13 
82 II Sorafenib 400mg 54 7.0 29 
Sorafenib 400mg 51 11.9 2 48 II 
Placebo 32 9.0 3 
CBDCA + Pac* 462 10.7 24 41 III 
CBDCA + Pac* + Sorafenib 400mg 464 10.6 30 
Vandetanib 
83 II Vandetanib 100mg/200mg/300mg 53 NR 13 
Vandetanib 300mg daily 83 6.1 8 42 II 
Gefitinib 250mg daily 85 7.4 1 
Docetaxel  41 13.4 12 
Docetaxel + vandetanib 100mg 44 13.1 26 
84 II 
Docetaxel + vandetanib 300mg 42 7.9 18 
CBDCA+Pac* 52 NR 25 
CBDCA+Pac*+ vandetanib 300mg 56  32 
85 II 
Vandetanib 73  7 
Sunitinib 
35 II Sunitinib 50 mg daily# 63 5.4 11.1 
50 II Sunitinib 37.5mg daily## 47 8.6 2 
49 I CDDP+gem** + sunitinib (37.5 or 50mg) 13 NR 23 
Motesanib 
CBDCA + Pac*+motesanib 50, 125, 75 2id  NR 17 
Pan*** + motesanib 50, 125, 75 2id  NR 0 
34 Ib 
CBDCA + Pac*+ Pan***+ motesanib 125 d  NR 17 
Axitinib 
52 II Axitinib 5 mg BID oral 32 14.8 32 
Abbreviations: n, number of patients; OS = overall survival; RR = response rate; NR = not reported; *CBDCA + Pac: Carboplatin + paclitaxel; **CDDP + gem: Cisplantin + gemcit-
abin; *** Panitumumab each every 21 days cycle; #sunitinib administered daily for 4 weeks of 6 weeks cycle; ##Sunitinib administered daily continuously for 4 weeks cycles. 
 
 











Fig. (2). Formula of the US7790729 patent. It is a compound that inhibits VEGFR and c-MET signaling. 
 
Table 4. Summary of New Relevant Patents on Anti-Angiogenic Drugs. 
# Invention Claim Publication date Patent reference (company) Reference 
1 Tirosine Kinase inhibitor Compounds and methods for inhibition 
of VEGFR and HGF receptor signal-
ing. The invention also provides com-
positions and methods for treating cell 
proliferative diseases and conditions 
Sep 07, 2010 US 7790729 
(Methylgene, Inc.) 
[78] 
2 Tirosine kinase inhibitor Inhibit VEGFR and treat cancer with 
VEGF over expression 
Jan 25, 2011 US 7875603 
(Nova Southeastern University, FL, 
USA) 
[39] 
3 Monoclonal antibody Anti-VEGF that inhibit with high 
affinity the binding of VEGF to 
VEGFR 
Apr 6, 2010 US 7691977 (Genentech, Inc.) [93] 
4 Monoclonal antibody Reduce angiogenesis by inhibiting 
PlGF pathways 
Jan 25, 2011 US 7875704 (Natarajan, Meera) [97] 
5 Monoclonal antibody 
(VC300) 
VC300 specifically binds  with high 
affinity to amino acid residues Asn 100 
to Lys 107 in human VEGF  
Jun 22, 2010 US 7740844 (Taiwan Liposome Co. 
Ltd) 
[92] 
6 Polypeptide sequence Potent  specific  inhibitor of  endothe-
lial proliferation and angiogenesis 
Jan 11, 2011 US 7867975 
(The Children's Medical Center Cor-
poration, Boston, USA)   
[53] 
7 Polypeptide sequence 
(VEGF165b) 
An isolated VEGF polypeptide having 
anti-angiogenic activity  
Oct 26, 2010 US 7820178 (University of Bristol, 
UK) 
[96] 
8 Adenovirus vector (Hu-
man si-hMet-Ad516) 
Produce significant reduction in tumor 
growth by inducing apoptosis 
Jan 18, 2011 US 7872117 
(Van Andel Research Institute, USA) 
[81] 
Abbreviations: VEGF , vascular endothelial growth factor; VEGFR, VEGF receptor; HGF, hepatocyte growth factor; CDR, complementarity determining region; USA, United States 
of America; UK, United Kingdom; PlGF, placental growth factor . 
 
the contribution of VEGF haplotypes (combinations of spe-
cific allelic variants in different polymorphism) in LC. This 
body of data emphasizes that some VEGF SNP variants may 
be LC biomarkers; however, some conflicting results have 
been reported in different studies, as some studies report 
statistically significant associations between VEGF poly-
morphic variants and tumor risk/behavior, while others fail 
to show this- see Table 5. This may be due to differences in 
study design and analysis, small sample sizes, different eth-
nic backgrounds across studies, and experimental and proce-
dural variations to assess, for example, VEGF gene variants, 
VEGF levels, and patient outcome. It is also clear that, de-
spite the unquestionable relevance of VEGF in tumors, par-
ticularly highly angiogenic neoplasms like LC, and the use 
of anti-angiogenic therapies in some of these tumors, there is 
still a very limited number of studies addressing the rele-
vance of VEGF polymorphisms in LC. Future well-designed, 
large, prospective studies are warranted to clearly establish 
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Table 5. Summary of VEGF Polymorphisms in Lung Cancer. 
Polymorphism Tumor 
Type 
No. Cases / 
Controls 
Ethnicity Effects on 
Tumor Risk* 
Functional and Clinical Effects 
(VEGF levels, Tumor Behavior, Survival)* 
Reference 
NSCLC 36 / 0 N/A N.Det. CA genotype increased tumor VEGF expression 
and vascular density 
[107] 
NSCLC 126 / 0 N/A N.Det. AA genotype associated with worse survival [112] 
rs699947 
(-2578 C/A) 
NSCLC 566 / 0 Asian N.Det. N.S. [110] 
rs1005230 
(-2489 C/T) 
NSCLC 566 / 0 Asian N.Det. N.S. [110] 









432 / 432 Asian N.S. N.Det. [111] 
NSCLC 1900 / 1458 Caucasian N.S. N.Det. [103] 
NSCLC 462 / 0 N/A N.Det. N.S. [108] 
rs833061 
(-460 C/T) 
NSCLC 126 / 0 N/A N.Det. CC genotype associated with worse survival [112] 
rs25648 
(-7 C/T) 
NSCLC 568 / 0 Asian N.Det. N.S. [110] 
NSCLC 36 / 0 N/A N.Det. GC genotype associated with increased tumor 




432 / 432 Asian GG genotype reduces 
risk of SCC 
N.Det. [110] 
NSCLC 1900 / 1458 Caucasian N.S. N.Det. [103] 
NSCLC 462 / 0 N/A N.Det. C allele associated with improved survival [108] 
NSCLC 462 / 0 N/A N.Det. GC and combined GC+CC genotypes associated 




88 / 0 N/A N. Det. N.S. [109] 
NSCLC 126 / 0 N/A N.Det. N.S. [112] 
rs2010963 
(405 G/C) 
NSCLC 566 / 0 Asian N.Det. N.S. [110] 
Lung 
cancer 
432 / 432 Asian CT or CT+TT genotypes 
reduce risk of SCC 
N.Det. [110] 
NSCLC 1900 / 1458 Caucasian N.S. N.Det. [103] 
NSCLC 462 / 0 N/A N.Det. N.S. [108] 
Lung 
cancer 
88 / 0 N/A N. Det. T allele increased VEGF gene expression and 
VEGF serum levels 
[109] 
NSCLC 126 / 0 N/A N.Det. N.S. [112] 
rs3025039 
(936 C/T)  
NSCLC 568 / 0 Asian N.Det. N.S. [110] 
rs10434 
(1612 G/A) 
NSCLC 560 / 0 Asian N.Det. N.S. [110] 

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(Table 5) Contd….. 
Polymorphism Tumor 
Type 
No. Cases / 
Controls 
Ethnicity Effects on 
Tumor Risk* 
Functional and Clinical Effects 
(VEGF levels, Tumor Behavior, Survival)* 
Reference 
rs833069 (in-
tron 2 G/A) 
NSCLC 560 / 0 Asian N.Det. N.S. [110] 
rs833070 (in-
tron 2 G/A) 
NSCLC 560 / 0 Asian N.Det. N.S. [110] 
rs3024994 
(intron 2 C/T) 
NSCLC 568 / 0 Asian N.Det. N.S. [110] 
rs3025010 
(intron 5 C/T) 
NSCLC 567 / 0 Asian N.Det. N.S. [110] 
rs3025035 
(intron 7 C/T) 
NSCLC 568 / 0 Asian N.Det. N.S. [110] 
rs3025040  
(3'-UTR  T/C) 
NSCLC 568 / 0 Asian N.Det. N.S. [110] 
rs3025053 
(3'-UTR G/A) 
NSCLC 568 / 0 Asian N.Det. N.S. [110] 
* - Significant differences were considered when P<0.05. 
Abbreviations: NSCLC, non-small cell lung cancer; SCC, small cell carcinoma; N/A, not available; N.Det., not determined; N.S., not significant. 
 
Table 6. Summary of VEGF Haplotypes in Lung Cancer. 




Ethnicity Effects on 
Tumor Risk* 
Functional and Clinical 
Effects (VEGF levels, Tu-
mor Behavior, Survival)* 
Reference 




432 / 432 Asian TCT reduces risk of 
lung cancer 
N.Det. [111] 




432 / 432 Asian TGT increases risk of 
lung cancer 
N.Det. [111] 
 Each haplotype vs all 
other haplotypes 
AC 432 / 432 Asian N.S. N.Det. [111] 
 CGT vs all other haplo-
types 
SCC 432 / 432 Asian CGT reduces risk of 
SCC 
N.Det. [111] 
 TCC vs all other haplo-
types 
SCC 432 / 432 Asian TCC increases risk of 
SCC 
N.Det. [111] 
 TCC vs CGC (reference) NSCLC 1900 / 1458 Caucasian N.S. N.Det. [103] 
 TGC vs CGC (reference) NSCLC 1900 / 1458 Caucasian N.S. N.Det. [103] 
 CGT vs CGC (reference) NSCLC 1900 / 1458 Caucasian N.S. N.Det. [103] 
 TCT vs CGC (reference) NSCLC 1900 / 1458 Caucasian N.S. N.Det. [103] 
405,936 All variant alleles vs GC 
(reference) 
NSCLC 462 / 0 N/A N.Det. higher number of variant 
alleles increased overall sur-
vival 
[108] 
* - Significant differences were considered when P < 0.05. 
Abbreviations: NSCLC, non-small cell lung cancer; AC, adenocarcinoma; SCC, small cell carcinoma; N/A, not available; N.Det., not determined; N.S., not significant. 
 
the biological and clinical implications of these polymor-
phisms in different types of LC, particularly how they affect 
tumor risk, progression, and response to therapies, especially 
those targeting angiogenesis-related molecules. 
6. CURRENT & FUTURE DEVELOPMENTS 
 Currently, many efforts are underway in order to develop 
new therapeutic strategies against LC based on its molecular 
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and clinical features. The treatment of NSCLC patients with 
anti-angiogenic agents, like bevacizumab, together with 
other agents [116], like gefitinib and erlotinib for EGFR-
positive tumors, has demonstrated how these fundamental 
new targeted therapies are in order to improve survival and 
the quality of life of these patients.  
 Combined chemotherapy composed by molecular thera-
pies as well as conventional chemotherapy have shown bet-
ter results in patients with NSCLC because they concurrently 
and synergistically act in different molecular pathways [32, 
116]. Many clinical trials [11, 32-35, 41, 42, 46-50, 52, 71, 
82-85, 87] have reported the beneficial impact of these com-
bined therapies as demonstrated in Table 3, commonly as-
sessed at the levels of OS and PFS [32, 117]. The VEGF, 
through either its serum levels [9] or its tumoral levels, has 
shown evidence of being a putative prognostic marker in 
NSCLC [28]. Several VEGF genetic polymorphisms related 
directly or indirectly to angiogenesis like the +936 C/T 
[109], the +405 G/C [108], and the - 460 T/C [111] poly-
morphism extend a certain impact to the prognosis and/or the 
risk level for NSCLC patients. However, currently there are 
still no satisfactory biomarkers capable of correlating to risk, 
to therapeutic response, or to prognosis of NSCLC patients, 
which is currently a challenge in the field of oncology. It is 
extremely important to better understand anti-cancer phar-
macogenomics in order to improve clinical practice. For this 
reason, more studies are necessary for a better understanding 
of the illness mechanisms and for the improvement of future 
therapeutic protocols, making it possible to evaluate, with 
reasonable accuracy and low expense, what type of treatment 
is best for each patient, as well as the potential NSCLC risk 
development.  
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ABBREVIATIONS USED 
VEGF = Vascular endothelial growth factor 
LC = Lung cancer  
NSCLC = Non small cell lung cancer 
PlGF = Placental growth factor 
VEGFR = VEGF receptor 
HIF = Hypoxia inducible factor 
Dll4 = Delta-like ligand 4 
OS = Overall survival  
PFS = Progression free survival 
EDTA = Ethylenediamine tetraacetic acid 
ICAM-1 = Intracellular cell adhesion molecule 1 
TKI = Tyrosine kinase inhibitor 
EGFR = Epigermal growth factor receptor 
FISH = Fluorescence in situ hybridization 
ASCO = American society of clinical oncology 
PIK3 = Phosphoinositide 3-kinase  
mTOR = Mammalian target of rapamycin  
EMEA = European Medicine Agency 
US = United States 
FDA = Food and drugs administration 
HGF = Hepatocyte growth factor 
KDR receptor = Kinase insert domain receptor 
CDR = Complementarity-determining region 
V h = Variable region 
SNP = Single nucleotide polymorphism 
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